Trial Profile
A phase III, double blind, randomised, placebo controlled study to assess the efficacy and safety of a single treatment of Clostridium botulinum toxin type A to improve the appearance of moderate to severe glabellar lines.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Jun 2022
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Glabellar lines
- Focus Therapeutic Use
- Sponsors Ipsen Limited
- 31 May 2022 According to a Galderma media release, Pooled data from two phase III studies (NCT02353871 and NCT02493946) will be presented at the upcoming International Master Course on Aging Science (IMCAS) World Congress 2022 in Paris from June 3-5, 2022.
- 10 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 24 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record